Winfield Associates’s Clovis Oncology, Inc. CLVS Stock Holding History

Winfield Associates’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-136	Closed	-$10K	–	714
2017 Q4	$10K	Buy	+136	New	+$9.51K	0.01%	429

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Winfield Associates's CLVS Position: Q1 2018 in Review

Winfield Associates sold out of Clovis Oncology, Inc. (CLVS) in Q1 2018, closing a stake of 136 shares — an estimated $10K sold.

Winfield Associates first reported a position in CLVS in Q4 2017 and held it in 1 quarter. The position peaked at $10K in Q4 2017. 229 funds tracked by Wall St. Rank hold CLVS as of Q1 2018.

Winfield Associates reported no remaining Clovis Oncology, Inc. position as of Q1 2018 after selling out during the quarter.
Winfield Associates sold 136 Clovis Oncology, Inc. shares in Q1 2018, an estimated $10K.
Winfield Associates first reported a position in Clovis Oncology, Inc. in Q4 2017 and held it in 1 quarter.
Winfield Associates's Clovis Oncology, Inc. position peaked at $10K in Q4 2017.
229 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2018.

Based on Winfield Associates's 13F filing for Q1 2018, filed 10 May 2018.